Clinical model: Interferons activate human monocytes to an eradicative tumor cell level in vitro

Journal of Interferon and Cytokine Research

Volumn 27, Issue 2, 2007, Pages 157-163

  Baron, Samuel ^a,d   Hernandez, Jessica ^b   Bekisz, Joseph ^b   Poast, Joyce ^a   Goldman, Neil ^b   Clouse, Kathleen ^c   Fields, Karen ^c   Bacot, Sylvia ^c   Wang, Jiun ^c   Zoon, Kathryn ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL VIOLET; CYTOKINE; GAMMA INTERFERON; INTERFERON;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIPLOIDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LEUKOCYTE; MONOCYTE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; IMMUNITY, NATURAL; INTERFERONS; LYMPHOCYTES; MACROPHAGE ACTIVATION; MODELS, BIOLOGICAL; MONOCYTES, ACTIVATED KILLER; NEOPLASMS;

EID: 33847128032     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.0083     Document Type: Article

References (65)

1. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons alpha, beta and omega. Growth Factors 2004;22:243-251.
2. Pang KR, Wu JJ, Huang DB, Tyring SK, Baron S. Biological and clinical basis for molecular studies of interferons. Methods Mol. Med. 2005;116:1-23.
3. Isaacs A. Interferon. Adv. Virus Res. 1963;10:1-38.
4. Pfeffer LM, Dinarello CA, Herbverman RB, Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489-2499.
5. Vilcek J, Feldmann M. Historical review: cytokines as therapeutics and targets of therapeutics. Trends Pharmacol. Sci. 2004;25:201-209.
6. Green JA, Copperband SR, Kibrick S. Immune specific induction of interferon production in cultures of human blood lymphocytes. Science 1969;164:1415-1417.
7. Dianzani F, Antonelli G, Capobianchi MR. Biological activity of gamma interferon. Ann. Ist. Sup. Sanita 1990;26:255-261.
8. Le Page C, Genin P, Baines MG, Hiscott J. Interferon activation and innate immunity. Rev. Immunogenet. 2000;2:374-386.
9. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, Pardoll DM, Housseau F. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 2006;12:207-213.
10. Marshall JD, Heeke DS, Abbate C, Yee P, Van Nest G. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunology 2006;117:38-46.
11. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell-independent antitumor effects. J. Immunol. 2006;176:309-318.
12. Alexander P, Evans R. Endotoxin and double-stranded RNA render macrophages cytotoxic. Nat. New Biol. 1971;232:76-78.
13. Fan D, Liaw A, Denkins YM, Collins JH, Van Arsdall M, Chang JL, Chakrabarty S, Nguyen D, Kruzel E, Fidler IJ. Type 1 transforming growth factor-beta differentially modulates tumoricidal activity of murine peritoneal macrophages against metastatic variants of the B16 murine melanoma. J. Exp. Ther. Oncol. 2002;2:286-297.
14. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002;62:5069-5075.
15. Berdel WE, Bausert WR, Weltzien HU, Modolell ML, Widmann KH, Munder PG. The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur. J. Cancer 1980;16:1199-1204.
16. Du C, Feng N, Jin H, Lee V, Wang M, Wright JA, Young AH. Macrophages play a critical role in the anti-tumor activity of Virulizin. Int. J. Oncol. 2003;23:1341-1346.
17. Kaplan AM, Morahan PS. Macrophage mediated tumor cell cytotoxicity. Ann. NY Acad. Sci. 1976;276:134-145.
18. Isaacs A, Westwood MA. Inhibition by interferon of the growth of vaccinia virus in the rabbit skin. Lancet 1959:324-325.
19. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin. Cancer Biol. 2000;10:125-144.
20. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003;3:666-675.
21. Andreesen R, Hennemann B. Adoptive immunotherapy with autologous macrophages: current status and future perspectives. Pathobiology 1991;59:259-263.
22. Bacot SM, Lenz P, Frazier-Jessen MR, Feldman GM. Activation by prion peptide PrP 106-126 induces a NF-kappaB-driven proinflammatory response in human monocyte-derived dendritic cells. J. Leukoc. Biol. 2003;74:118-125.
23. Gerrard TL, Jurgensen CH, Fauci AS. Differential effect of monoclonal anti-DR antibody on monocytes in antigen- and mitogen-stimulated responses: mechanism of inhibition and relationship to interleukin 1 secretion. Cell. Immunol. 1983;82:394-402.
24. Hibbs JB Jr, Chapman HA Jr, Weinberg JB. The macrophage as an antineoplastic surveillance cell: biological perspectives. J. Reticuloendothel. Soc. 1978;24:549-570.
25. Russell SW, Doe WF, McIntosh AT. Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors. J. Exp. Med. 1977;146:1511-1520.
26. Wahl LM, Katona IM, Wilder RL, Winter CC, Haraoui B, Scher I, Wahl SM. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-entriched fractions by flow cytometric analysis. Cell Immunol. 1984;85:373-383.
27. Wahl SM, Katona IM, Stadler BM, Wilder RL, Helsel WE, Wahl LM. Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). II. Functional properties of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions. Cell. Immunol. 1984;85:384-395.
28. Chang ZL, Hoffman T, Stevenson HC, Trinchieri G, Herberman RB. Characterization by monoclonal antibodies of the cytotoxic effector cells in human peripheral blood mononuclear cells reactive against anchorage-dependent tumour cell lines. Scand. J. Immunol. 1983;18:451-459.
29. Colotta F, Peri G, Villa A, Mantovani A. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage. J. Immunol. 1984;132:936-944.
30. Gerrard TL, Terz JJ, Kaplan AM. Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients. Int. J. Cancer 1980;26:585-593.
31. Horowitz DA, Bakke AC, Abo W, Nishiya K. Monocyte and NK cell cytotoxic activity in human adherent cell preparations: discriminating effects of interferon and lactoferrin. J. Immunol. 1984;132:2370-2374.
32. Villa A, Peri G, Rossi V, Delia D, Mantovani A. Monoclonal antibody-defined surface markers of effector cells involved in human monocyte cytotoxicity. Cell. Immunol. 1984;87:494-503.
33. Zoon KC, Zur Nedden DL, Enterline JC, Manischewitz JF, Dyer DR, Boykins RA, Bekisz J, Gerrard TL. Chemical and biological characterization of natural human lymphoblastoid interfron alphas. In: Cantell K, Schellekens H, eds. 1986 ISIR-TNO Meeting on the Interferon System. Espoo, Finland: Martinus Nijhoff Publishers, 1986:567-569.
34. Ramamurthy V, Fleischmann WR Jr. Independent regulation of the antiviral states induced by MuIFN-alpha/beta and by MuIFN-gamma. J. Gen. Virol. 1986;67:2223-2226.
35. Wang LX, Chen BG, Plautz GE. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J. Immunol. 2002;169:3314-3320.
36. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin. Cancer Res. 2000;6:2268-2278.
37. Olstad R, Kaplan G, Seljelid R. In vitro cytotoxicity of mouse macrophages activated by coculture with syngeneic sarcoma cells. Scand. J. Immunol. 1982;16:421-430.
38. Suzuki T, Yoshie H, Jeannel D, Tortevoye P, Fournier S, Dupont B, deThe G HK. Detection of intracellular p24-positive macrophages in gingival crevicular fluid from periodontal lesions of stage IV AIDS patients. AIDS 1996;10:804-805.
39. Ballinger MN, Paine IR, Serezani CH, Aronoff DM, Choi Es, Standiford TJ, Toews GB, Moore BB. Role of GM-CSF during gram-negative lung infection with Pseudomonas aeruginosa. Am. J. Respir. Cell Mol. Biol. 2006;34:766-774.
40. Boyle MD, Ormerod MG. Destruction of allogeneic tumor cells by peritoneal macrophages. Transplantation 1976;21:242-246.
41. Burke DS, Fowler AK, Redfield RR, Dilworth S, Oster CN. Isolation of HIV-1 from the blood of seropositive adults: patient stage of illness and sample inoculum size are major determinants of a positive culture. The Walter Reed Retroviral Research Group. J. Acquir. Immune Defic. Syndr. 1990;3:1159-1167.
42. Metchnikoff E. www.britannica.com/search?query=Metchnikoff &ct= Encyclopaedia Britannica Premium Service, 2006.
43. Andreesen R, Scheibenbogen C, Brugger WB, Krause SW, Meerpohl H-G, Leser H-G, Engler H, Lohr GW. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 1990;50:7450-7456.
44. Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 2006;6:123-133.
45. Webb DSA, Gerrard TL. IFN-apha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J. Immunol. 1990;144:3643-3648.
46. Fidler IJ. Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res. 1974;34:1074-1078.
47. Lasek W, Basak G, Switaj T, Jakubowska AB, Wysocki PJ, Mackiewica A, Drela N, Jalili A, Kaminski R, Kozar k, Jakobisiak M. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol. Immunother. 2004;53:363-372.
48. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 2002;44:143-161.
49. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
50. Hibbs JB Jr, Lambert LH Jr, Remington JS. Adjuvant induced resistance to tumor development in mice. Proc. Soc. Exp. Biol. Med. 1972;139:1053-1056.
51. Hibbs JB Jr, Lambert LH Jr, Remington JS. Possible role of macrophage-mediated nonspecific cytotoxicity in tumour resistance. Nat. New Biol. 1972;235:48-50.
52. Hibbs JB Jr, Lambert LH Jr, Remington JS. In vitro nonimmunologic destruction of cells with abnormal growth characteristics by adjuvant activated macrophages. Proc. Soc. Exp. Biol. Med. 1972;139:1049-1052.
53. Hibbs JB Jr, Lambert LH Jr, Remington JS. Control of carcinogenesis: a possible role for the activated macrophage. Science 1972;177:998-1000.
54. Larabi M, Legrand P, Appel M, Gil S, Lepoivre M, Devissaguet J, Puisieux F, Barratt G. Reduction of NO synthase expression and tumor necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Antimicrob. Agents Chemother. 2001;45:553-562.
55. Bartholeyns J, Lombard Y, Poindron P. Immunotherapy of murine sarcoma by adoptive transfer of resident peritoneal macrophages proliferating in culture. Anticancer Res. 1988;8:145-151.
56. Bartholeyns J, Lopez M. Immune control of neoplasia by adoptive transfer of macrophages: potentiality for antigen presentation and gene transfer. Anticancer Res. 1994;14:2673-2676.
57. Ebina T, Fujimiya Y, Yamaguchi T, Ogama N, Sasaki H, Isono N, Suzuki Y, Katakura R, Tunaka K, Nagata K, Takano S, Tamura K, Uno K, Kishida T. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. Biotherapy 1998;11:241-253.
58. Eymard JC, Lopez M, Cattan A, Bouche O, Adjizian JC, Bernard J. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer. Eur. J. Cancer 1996;32A:1905-1911.
59. Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol. Immunother. 2004;53:262-274.
60. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 2005;175:1197-1205.
61. Krause SW, Zaiss M, Kreutz M, Andreesen R. Activation of lymphocytes inhibits human monocyte to macrophage differentiation. Immunobiology 2001;203:709-724.
62. Peri G, Polentarutti N, Sessa C, Mangioni C, Mantovani A. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin. Int. J. Cancer 1981;28:143-152.
63. Gouwy M, Struyf S, Proost P, Van Damme J. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev. 2005;16:561-580.
64. Kobaynshi M, Tsuda Y, Yoshida T, Takeuchi D, Utsunomiya T, Takahashi H, Suzuki F. Bacterial sepsis and chemokines. Curr. Drug Targets 2005;6:119-134.
65. Ramana CV, Gil MP, Schreiber RD, Stark GR. Stall-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol. 2002;23:96-101.